Molecular Profiles opens new facility in England
The new plant, which has been inspected by the Medicines and Healthcare products Regulatory Agency (MHRA), is intended to provide access to clinical manufacturing capabilities for all the
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The Department of Industrial Policy & Promotion (DIPP), and the Department of Pharmaceuticals, including healthcare experts from the public health foundation of India, will participate in the discussion,
The recalled prescription only medicines include Erythromycin, Metformin, Atenolol, Pramipexole, Risperidone and Clopidogrel among others. MHRA Inspection, Enforcement and Standards director Gerald Heddell said that the move was